SynthesisAnnals of surgery2024
The Impact of Portal Hypertension Assessment Method on the Outcomes of Hepatocellular Carcinoma Resection: A Meta-Analysis of Matched Cohort and Prospective Studies.
Synthesis in Annals of surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Von Willebrand Factor Antigen Improves Risk Stratification for Patients with a Diagnosis of Resectable Hepatocellular Carcinoma.Annals of surgical oncology · 2024Trial
- Cirrhosis, portal hypertension and hepatocellular carcinoma: a stage-based approach.Nature reviews. Gastroenterology & hepatology · 2026Review
- Refining the role of liver transplantation as a curative treatment for hepatocellular carcinoma.International journal of clinical oncology · 2026Review
- Identifying the Optimal Treatment for Patients with Hepatocellular Carcinoma and Clinically Significant Portal Hypertension: A Multicenter Propensity Score-Weighted Analysis.Annals of surgical oncology · 2026Article
- Stage-specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma.Hepatology international · 2025Article
- Surgical resection for hepatocellular carcinoma in cirrhotic patients with clinically significant portal hypertension: a multidisciplinary team decision.Hepatobiliary surgery and nutrition · 2025Article
- Rethinking portal hypertension in hepatocellular carcinoma resection: a gradient of risk beyond black and white.Hepatobiliary surgery and nutrition · 2025Article
- Clinically Evident Portal Hypertension Is an Independent Risk Factor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation.Journal of clinical medicine · 2025Article
- Application of propensity score matching in prognostic analysis of portal hypertension in hepatocellular carcinoma patients.Frontiers in oncology · 2025Article
- Current strategies for predicting post-hepatectomy liver failure and a new ultrasound-based nomogram.World journal of gastroenterology · 2024Article
- ASO Author Reflections: Von Willebrand Factor for Assessment of Portal Hypertension and Perioperative Risk in Resectable HCC.Annals of surgical oncology · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveExamine portal hypertension (PHT) impact on postoperative and survival outcomes in hepatocellular carcinoma (HCC) patients after liver resection (LR), specifically exploring distinctions between indirect signs and invasive measurements of PHT.
backgroundPHT has historically discouraged LR in individuals with HCC due to the elevated risk of morbidity, including liver decompensation (LD).
methodsA systematic review was conducted using 3 databases to identify prospective-controlled and matched cohort studies until December 28, 2022. Focus on comparing postoperative outcomes (mortality, morbidity, and liver-related complications) and overall survival in HCC patients with and without PHT undergoing LR. Three meta-analysis models were utilized: for aggregated data (fixed-effects inverse variance model), for patient-level survival data (one-stage frequentist meta-analysis with gamma-shared frailty Cox proportional hazards model), and for pooled data (Freeman-Tukey exact and double arcsine method).
resultsNine studies involving 1124 patients were analyzed. Indirect signs of PHT were not significantly associated with higher mortality, overall complications, PHLF or LD. However, LR in patients with hepatic venous pressure gradient (HVPG) ≥10 mm Hg significantly increased the risk of overall complications, PHLF, and LD. Despite elevated risks, the procedure resulted in a 5-year overall survival rate of 55.2%. Open LR significantly increased the risk of overall complications, PHLF, and LD. Conversely, PHT did not show a significant association with worse postoperative outcomes in minimally invasive LR.
conclusionsLR in the presence of indirect signs of PHT poses no increased risk of complications. Yet, in HVPG ≥10 mm Hg patients, LR increases overall morbidity and liver-related complications risk. Transjugular HVPG assessment is crucial for LR decisions. Minimally invasive approach seems to be vital for favorable outcomes, especially in HVPG ≥10 mm Hg patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.